Dermata Therapeutics, Inc. (DRMA) has a consensus analyst rating of Buy, based on 1 analyst covering the stock. Of those, 1 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for DRMA is $6.00, representing a +380.0% upside from the current price of $1.25. Price targets range from a low of $6.00 to a high of $6.00.
